Michelle J. Shapiro will speak on the “Health Care Fraud Enforcement: Examining the Current Era” panel at the Boston Bar Association’s (BBA) 2026 White-Collar Crime Conference.
Everyone is talking about peptides. Your doctor, your trainer, that guy at the dinner party who swears that BPC-157 rebuilt his knee — peptides have officially entered the zeitgeist. But for every breathless testimonial, there is a thicket of regulations that most market participants barely understand.
On April 18, President Trump signed an executive order (EO) directing multiple federal agencies to accelerate research and expand access to psychedelic drugs as potential treatments for serious mental health conditions. The EO represents a notable shift in federal policy toward psychedelic substances and their potential therapeutic use.
The Federal Trade Commission (FTC) is signaling that health care and life sciences companies should expect heightened regulatory scrutiny related to consumer protection and competition.
Welcome to the April 2026 issue of “As the (Customs and Trade) World Turns,” our monthly newsletter where we compile essential updates from the customs and trade world over the past month. We bring you the most recent and significant insights in an accessible format, concluding with our main takeaways — aka “And the Fox Says…” — on what you need to know.
In a recent ruling out of the District of Minnesota, a federal magistrate judge directed UnitedHealthcare (UHC) to turn over an expansive set of documents in the class action Estate of Lokken v. UnitedHealth Group, Inc., alleging that the health insurer used an artificial intelligence (AI) algorithm to improperly withhold post-acute care coverage from Medicare Advantage enrollees.
ArentFox Schiff’s Pat Naples discusses with Medical Economics the US Centers for Medicare & Medicaid Services’ (CMS) expanded anti‑fraud enforcement and its impact on health care providers.
Michelle J. Shapiro to speak at Executive Women in Bio (EWIB) virtual program – Implementing Lessons Learned From Enforcement Developments to Improve Corporate Compliance.
On March 9, a federal court in Connecticut issued a decision in Abira Medical Laboratories LLC v. Aetna Inc. et al. that underscores the continuing importance of clear and comprehensive assignment-of-benefits language in payer disputes.
ArentFox Schiff, in collaboration with Consilio, will host the 2026 Chicago Pharma Forum on May 6, 2026, bringing together pharmaceutical industry leaders and in‑house counsel in the Chicago area for a full day of discussion and networking.
Health Care Industry Group Co-Leader Annie Chang Lee will kick off the California Ambulatory Surgery Association’s (CASA) Administrator Mastery Series as the inaugural speaker on March 25, 2026.
Health Care Industry Co-Leader Nadia Patel was quoted on Johnson & Johnson’s Janssen Products LP unit’s appeal to the Third Circuit Court of Appeals to overturn the 2025 jury $1.6 billion verdict — the largest False Claims Act (FCA) judgment in history.
As we continue to move through 2026, the life sciences landscape is shaped by a convergence of regulatory, enforcement, and market access developments that demand heightened attention from industry stakeholders.